Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.19
-0.01 (-0.83%)
At close: Sep 26, 2025, 10:58 AM
-0.83% (1D)
| Bid | 1.19 |
| Market Cap | 264.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -236.91M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -1.08 |
| Forward PE | -1.38 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.2 |
| Volume | 663,913 |
| Avg. Volume (20D) | 4,098,333 |
| Open | 1.22 |
| Previous Close | 1.20 |
| Day's Range | 1.19 - 1.22 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.36 |
| Ex-Dividend Date | n/a |
About ALLO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAllogene Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+8.55%
Allogene Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
-15.68%
Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.
1 month ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy ...
